Table 4.

Differences in Children's Oncology Group–National Cancer Institute Pediatric Molecular Analysis for Therapy Choice trial and AcSé-European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children trial designs

	Pediatric-MATCH	AcSé-ESMART
Sequencing platform	One uniform targeted panel	Multiple panels from different sequencing studies
Matching method	Automated matching	Tumor board discussion
Treatments	Single-agent	Combination with chemotherapy
Targets (drug)	TSC1, TSC2, PI3K/mTOR (LY3023414)Mismatch repair (Olaparib)NTRK1/2/3 (Larotrectinib)EZH2, SMARCB1, SMARCA4 (Tazemetostat)MAPK pathway (Selumetinib)ALK, ROS1 (Ensartinib)BFAF V600 (Vemurafenib)	mTORC1/TORC2 (Arm 1 AZD2014)mTORC1/TORC2 (Arm 2 AZD2014 + Topotecan + Temozolomide)Mismatch repair defect in WEE1 (AZD1775 + Carboplatin)Mismatch repair defect in PARP (Olaparib + Irinotecan)CDK4/6 (Arm 1 Ribociclib and Topotecan + Temozolomide)CDK4/6 (Arm 2 Ribociclib and Everolimus)PD1 (Nivolumab + cyclophosphamide ± radiation)

AcSé-ESMART, Secured Access Program of the French National Cancer Institute (INCa); ESMART, European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children; mTOR, mammalian target of rapamycin, PARP, poly ADP ribose polymerase.